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A B S T R A C T
Photodynamic therapy (PDT) is an evolving method of treating superﬁcial tumours that is non-invasive
and carries minimal risk of toxicity. It combines tumour-selective photosensitiser dyes, tissue oxygen and
targeted illumination to generate cytotoxic reactive oxygen species (ROS) within the tumour. In addition
to directly acting on tumour cells, PDT damages and restricts tumour microvasculature, and causes a local
inﬂammatory response that stimulates an immune response against the tumour. Unlike surgery or
radiotherapy, the surrounding extracellular matrix is unaffected by PDT; thus, tissue healing is excellent
and PDT seldom causes scars. This, combined with the ease of light application, has made PDT a popular
treatment for cancers and pre-cancerous conditions in human beings. Moreover, because photosensitiser
dyes are ﬂuorescent and selectively accumulate in tumour tissues, they can additionally be used to
visualise and discriminate tumour from normal tissues, thereby improving the accuracy of tumour
surgery. In veterinary practice, PDT has been used successfully for treatment of superﬁcial squamous cell
carcinomas of the feline nasal planum; urinary tract, urinary bladder and prostate neoplasia in dogs; and
equine sarcoids. The purpose of this article is to provide a comparative review of the current literature on
PDT in human and veterinary medicine, and to establish a basis for future development of PDT in
veterinary medicine.
© 2017 Elsevier Ltd. All rights reserved.
Introduction
Photodynamic therapy (PDT) involves administration of a
photosensitiser drug, or a pro-drug, which selectively accumulates
in target cells, followed by local illumination of the lesion with
visible light (Luksiene, 2003; Wachowska et al., 2011). It is a
minimally invasive therapeutic technique used in the management
of various cancerous and pre-malignant diseases. The photo-
sensitiser can also be visualised in tumour cells using an
appropriate set of imaging ﬁlters to provide a means of tumour
detection (Hefti et al., 2010; Mowatt et al., 2011; Nguyen and Tsien
2013; Allison 2016).
In addition to cancer treatment, PDT has been used for the
treatment of microbial infections in human beings (Kharkwal et al.,
2011; Sharma et al., 2012; Wardlaw et al., 2012), dogs (Fabris et al.,
2014) and sheep (Sellera et al., 2016). PDT has also been used for
light-triggered uptake of pharmaceutical agents that otherwise
would become entrapped and destroyed within cellular endo-
somes (photochemical internalisation, PCI; Selbo et al., 2015;
Madsen, 2016).
The origins of PDT can be traced back to ancient Egypt, where
photosensitising plant pigment extracts were applied to the skin
and exposed to sunlight as a treatment for psoriasis (Daniell and
Hill, 1991). The use of PDT for treatment of various human skin
cancers was ﬁrst investigated in the 1970s by Dougherty et al.
(1978). Thomas Dougherty’s use of a haematoporphyrin derivative
was based on the pioneering work of Policard (1924), who
demonstrated that porphyrins were preferentially distributed into
malignant rather than normal tissues. The technique was slow to
gain acceptance because the ‘ﬁrst generation’ photodynamic
agents were slow to clear from normal cells, with the result that
treated human patients had to remain out of bright light (e.g.,
sunlight) for several weeks to avoid severe skin reactions.
However, the potential for the technique in treating locally
advanced carcinomas of the head and neck (Wile et al., 1984),
urinary bladder (Misaki et al., 1983), oesophagus and bronchus
(Cortese and Kinsey, 1984) outweighed this caveat and stimulated
further research.
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The availability of haematoporphyrin derivatives with faster
tissue clearance times stimulated more interest in PDT and
numerous human clinical trials have now been published, showing
encouraging results with photosensitising dyes administered
topically or systemically (orally or intravenously) or instilled into
hollow organs (e.g. urinary bladder). A limited number of
veterinary studies have been published, also showing promise. A
previous review of PDT in veterinary medicine was published by
Buchholz and Walt (2013); since then, further advances have been
made. The purpose of this review is to describe the basic principles
of PDT and discuss the clinical application of PDT in human beings
and animals for cancer treatment and diagnosis.
Fundamentals and mechanisms
There are three basic requirements for PDT: (1) a compound
with photosensitising properties (photosensitiser, PS); (2) a source
of visible light; and (3) oxygen. The photosensitiser is a chemical/
dye that selectively accumulates in malignant tissues and can be
activated by visible light. Energy from the light-excited PS is
transferred to oxygen molecules (O2) to give reactive oxygen
species (ROS), notably singlet oxygen (1O2) and superoxides, which
damage biological molecules, initiating a cascade of biochemical
events, culminating in damage and death of neoplastic cells (Fig. 1)
(Dougherty et al., 1998; Juzeniene et al., 2007). Increasing tissue
oxygenation can lead to increased ROS formation during PDT and
improved outcomes (Maier et al., 2000).
The mechanisms by which different photosensitisers localise
selectively in malignant tissues are complex and not fully
understood. Physical factors, such as increased vascular perme-
ability and poor lymphatic drainage in tumours, coupled with an
afﬁnity for proliferating endothelium, are likely to contribute to
their accumulation in tumours (Dougherty et al., 1998).
Three main processes by which ROS contribute to the
destruction of tumours by PDT are direct cellular damage, indirect
vascular shutdown and activation of immune responses against
tumour cells (Dougherty et al., 1998; Dolmans et al., 2003; Solban
et al., 2006). Direct damage to tumour cells can result in cell death
by both programmed pathways (apoptosis) and non-programmed
pathways (necrosis) (Oleinick et al., 2002; Igney and Krammer,
2002; Allison and Moghissi, 2013a). Generally, when the light
intensity is low, apoptotic cell death may be initiated (Agarwal
et al., 1991; Allison and Moghissi, 2013b). At higher light
intensities, tumour cells are rapidly ablated by necrosis due to
destruction of cellular and subcellular membranes. This also leads
to release of cytokines and lysosomal enzymes (Henderson and
Fingar, 1987), causing damage to cells nearby, the so-called
bystander effect (Dahle et al., 1997; Allison and Moghissi, 2013a).
Release of inﬂammatory mediators from the treated region
stimulates activation of leucocytes, including neutrophils and
macrophages, and signiﬁcant tumour cell death occurs through
these activated immune cells (Coutier et al., 1999; Gollnick et al.,
2003; Castano et al., 2006). This observation has led to the
development of combination therapies of PDT with
Fig. 1. Fundamentals of photodynamic therapy. (A) Visible and near infra-red light spectrum showing the wavelengths (nm) of maximum tissue penetration by light (above)
and absorbance maxima of selected photosensitisers (below). (B–D) Chemical structures of selected photosensitisers. (E) Mechanism of action of photosensitising agents. The
photosensitiser (PS) becomes activated (PS*) by light (hy). PS* can undergo two types of reaction. In type I reactions, biological material (BM) interacts directly with PS*
forming ion radicals of both species (PS and BM+). The BM radical interacts with oxygen and becomes oxidised. The PS radical is either destroyed or reacts with oxygen to
regenerate PS and make a superoxide anion (O2) that can react with BM to oxidise it. In type II reactions, PS* interacts with oxygen to regenerate PS and make singlet oxygen
(1O2), which reacts with BM to oxidise it.
J. Dobson et al. / The Veterinary Journal 233 (2018) 8–18 9
immunotherapy, by including immunoadjuvants against tumour-
speciﬁc epitopes (Qiang et al., 2008; Kleinovink et al., 2015).
PDT also mediates a vascular effect within tumours (McMahon
et al., 1994; Abels, 2004). Neovascular tumour endothelial cells
may accumulate higher levels of PS than normal endothelium
(Debefve et al., 2011) and, following PDT, microvascular collapse
can be observed and can lead to severe and persistent post-PDT
tumour hypoxia (Star et al., 1986; Henderson and Fingar, 1987;
Chen et al., 2003). PDT may also lead to vessel constriction via
inhibition of the production or release of nitric oxide by the
endothelium (Gilissen et al., 1993).
An important clinical consideration is effective analgesia. In
human beings, PDT produces a sensation of stinging or burning
during illumination, especially in sensitive areas, such the face and
scalp (Halldin et al., 2011; Chaves et al., 2012). Treatment of large
skin areas generally produces more pain than smaller areas
(Grapenglesser et al., 2002; Halldin et al., 2011; Chaves et al., 2012).
Photosensitisers for photodynamic therapy
Photosensitising agents are natural or synthetic chemicals that
transfer light energy to neighbouring molecules, importantly to
dissolved oxygen (Allison et al., 2004). Most of the photosensitisers
used in cancer therapy are based on a tetrapyrrole structure,
similar to that of the protoporphyrin contained in haemoglobin. In
clinical practice, a successful PS agent is: (1) nontoxic until light
activated; (2) hydrophilic for easy systemic application; (3)
activated by a clinically useful light wavelength; and (4) reliably
generates a photodynamic reaction (PDR). Ideally, it also concen-
trates in tumours, clears normal tissue quickly and is eliminated
from the patient relatively rapidly (Allison and Moghissi, 2013a).
The ﬁrst-generation photosensitiser haematoporphyrin deriva-
tive (HPD) was a mixture of various monomers, dimers, and
polymers of haematoporphyrin (Allison and Moghissi, 2013a). The
commercially available product, porﬁmer sodium, marketed under
the tradename Photofrin, was used experimentally in healthy dogs
(Tochner et al., 1991; Panjehpour et al., 1993) and in a canine
glioma model (Whelan et al., 1993). It was approved for treatment
of early stage human lung cancer in 1998 and for Barrett’s
oesophagus in 2003. The clinical application of Photofrin has been
limited by two factors. First, its absorption peak occurs at 630 nm,
which is too short a wavelength to allow deep penetration of light
in tissue. Secondly, Photofrin results in cutaneous photosensitivity
lasting up to six weeks (Zhu and Finlay, 2008).
These limitations stimulated the development of a second
generation of photosensitisers with improved efﬁciency of ROS
generation, more rapid clearance, fewer side effects, and absorp-
tion peaks at longer wavelengths (>630 nm red light), where the
tissue penetration of light is deeper. One such second-generation
photosensitiser is 5-aminolaevulinic acid (ALA), a naturally
occurring pro-photosensitiser and precursor for the biosynthesis
of the haem molecule. For therapeutic purposes, ALA is adminis-
tered topically (Morton et al., 2008, 2013), orally (Muller and
Wilson, 2006), or intralesionally (Hage et al., 2007; Kim et al.,
2012). ALA enters into all cells, but uptake is potentiated by
transporters of b amino acids and g-aminobutyric acid (GABA)
(Rud et al., 2000), which are highly expressed on some cancer cells
and neurones, respectively (Zhang et al., 2013). It is then
metabolised to the red-ﬂuorescent photosensitiser protoporphyrin
IX (PpIX, absorption at 635 nm) and ﬁnally to non-ﬂuorescent
haem (Ajioka et al., 2006; Allison and Moghissi, 2013a). This ﬁnal
step relies on ferrochelatase to add ferrous iron (Fe2+) to PpIX; this
rate-limiting enzyme is often deﬁcient in cancer cells (Kemmner
et al., 2008). Thus, in the presence of excess ALA, cancer cells that
combine high ALA uptake with low PpIX destruction will
accumulate PpIX photosensitiser (Collaud et al., 2004). Clinical
advantages of ALA treatment include rapid clearance of PpIX from
the tissue within 12 h, resulting in short-lived cutaneous photo-
sensitivity. In human patients, ALA has been used for the treatment
of cutaneous T cell lymphoma (Coors and von den Driesch, 2004),
basal cell carcinoma (Kim et al., 2012), squamous cell carcinoma
(SCC) and other head and neck cancers (Grant et al., 1993; Morton
et al., 1996). In veterinary medicine, ALA has been used to treat SCC
in a cow (Hage et al., 2007) and in cats (Bexﬁeld et al., 2008),
sarcoids in horses (Gustafson et al., 2004; Golding et al., 2017) and
transitional cell carcinoma (TCC) in dogs (Lucroy et al., 2003a,b)
(Tables 1 and 2).
The hydrophilic nature of ALA limits its ability to penetrate
intact skin deeply and thereby restricts the use of topically applied
ALA-PDT to the treatment of superﬁcial diseases where the tissue
structure is disorganised. To overcome this limitation, ALA esters,
which are less hydrophilic than the parental compound, have been
developed. The methyl ester of ALA, methyl-aminolaevulinate
(MAL, Metvix, or Metvixia), was approved by the US Food and Drug
Administration (FDA) for PDT treatment of actinic keratosis in
2004 and has shown good results in treatment of equine sarcoids
(Kemp-Symonds, 2012; Golding et al., 2017). Hexaminolaevulinate,
the n-hexyl ester of ALA (HAL, Hexvix, Cysview), which is
converted to PpIX 50–100 times more efﬁciently than ALA, was
licensed in the US in 2010 for the detection of human urinary
bladder cancer (Furre et al., 2005). Hexaminolaevulinate has also
been used intra-operatively in a PDT model in dogs with prostate
carcinoma (L’Eplattenier et al., 2008).
Several other second-generation photosensitisers have been
developed, or are in the process of being developed, each with
slightly different origins and characteristics. These include
m-tetrahydroxophenyl chlorine (m-THPC, Foscan), 2-(1-hexylox-
yethyl)-2-devinyl pyropheophorbide-a (HPPH, Photochlor),
palladium bacteriopheophorbide (Padoporﬁn, TOOKAD) and its
more water-soluble monolysotaurine derivative (Padeliporﬁn,
TOOKAD-Soluble), motexaﬁn lutetium (Lu-Tex, Lutrin); and
Verteporﬁn (Visudyne). The advantages and indications for these
newer agents are summarised in Table 1.
Photosensitisers for tumour diagnosis
Photodynamic diagnosis (PDD) uses the ﬂuorescence of photo-
sensitisers to identify tumour tissue in situ. PDD ﬁts within the
broader category of ﬂuorescence guided surgery (Allison, 2016),
the distinction being that, by increasing the illumination intensity
or duration, PDD can become PDT. However, whilst the generation
of singlet oxygen by photosensitisers is essential for PDT, these
same reactive species can damage the photosensitiser and render it
non-ﬂuorescent.
ALA has been trialled for PDD in 11 different human tumour
types (Nokes et al., 2013) and is licensed in human beings for
intraoperative margin assessment in gliomas (Hefti et al., 2010;
Stummer et al., 2006) and the n-hexyl derivative for urinary
bladder cancer (Kausch et al., 2010; Mowatt et al., 2011). Each of the
major surgical microscopy and endoscopy manufacturers (Leica,
Olympus, Storz, and Zeiss) have specialised imaging equipment for
intraoperative PDD for human surgery. Research versions are
available for animal models (e.g. Solaris system, Perkin Elmer).
However, relatively little work has been done on translating
human PDD to veterinary surgery. Veterinary examples include
intraoperative cancer imaging and staging in dogs (Knapp et al.,
2007; Cabon et al., 2016; Osaki et al., 2016), and image-guided
surgery in cats (Wenk et al., 2013). The next generation of agents
for photodiagnosis are generally based on near infra-red dyes,
which allow deeper views into tissues, sometimes complexed with
tumour-targeting peptides or antibodies (Luo et al., 2011; Wenk
et al., 2013).
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Light sources and delivery systems
The primary requirement when treating lesions with PDT is to
ensure that sufﬁcient, homogenous light is delivered to the target
tissue. Each PS has an optimal wavelength and intensity (ﬂuence)
of light for activation (Sibata et al., 2001). Choice of light source
should therefore be based on PS absorption (ﬂuorescence
excitation and action spectra), location, size and accessibility of
lesions, and tissue characteristics. The clinical efﬁcacy of PDT is
dependent on complex dosimetry, comprising total light dose, light
exposure time and light delivery mode (single versus fractionated
or even metronomic). The ﬂuence rate also affects PDT response
(Henderson et al., 2006), as demonstrated in tumour bearing cats
by Hahn et al. (1998).
The wavelength of light used for PDT is typically in the range of
600–800 nm, the ‘therapeutic window’ (Wilson and Patterson,
1990). In this wavelength range, the energy of each photon (1.5 eV)
is sufﬁcient to excite the photosensitiser and yet is low enough to
allow the light to penetrate up to 2 cm into the tissue (Zhu and
Finlay, 2008).
Table 1
Summary of characteristics and application of selected second generation photosensitisers to treat tumours.
Agent (synonyms), manufacturer Activation wavelength
(nm)
Advantages Applicationsa References
Foscan (m-tetrahydroxophenyl chlorine (mTHPC),
temoporphin), Biolitec Pharma
525–660 Short duration of skin photosensitivity
(15 days)
Pleural mesothelioma Friedberg et al. (2003)
High quantum yield for singlet oxygen Head and neck cancers Biel (2006)
Depth of tumour necrosis (10 mm) Oesophageal cancer Etienne et al. (2004);
Lovat et al. (2005)
Prostatic cancer Nathan et al. (2002);
Moore et al. (2006)
Pancreatic cancer Pereira et al. (2007)
Skin tumours Triesscheijn et al.
(2006)
Skin tumours (cats) Buchholz et al. (2007)
Photochlor (2-(1-hexyloxyethyl)-2-devinyl
pyropheophorbide (HPPH)), AdooQ Bioscience
665–680 Extremely hydrophobic, increasing
penetration into tissue
Obstructive
oesophageal cancer
Dougherty et al. (2000)
Oral SCC (dogs) McCaw et al. (2000)
Facial SCC (cats) Magne et al. (1997)
SCC (horses) Giuliano et al. (2008)
TOOKAD (WST-09, Padoporﬁn, palladium
bacteriopheophorbide), Steba Biotech
760 New generation photosensitiser with
greater stability and short half-life
Prostatic carcinoma
(dogs)
Huang et al. (2005);
Nomura and Mimata
(2012)
Padeliporﬁn (TOOKAD Soluble, WST-11, palladium
bacteriopheophorbide monolysotaurine), Steba
Biotech
760 Vascular-targeted PDT Prostatic carcinoma Azzouzi et al. (2017)
Prostatic carcinoma
(dogs)
Chevalier et al. (2013)
Lu-Tex (Motexaﬁn lutetium, lutetium texaphyrin,
Pharmacyclics
730 Water soluble. Selectively retained in
tumour
Prostatic carcinoma Patel et al. (2008)
Only 24–48 h skin photosensitivity Rectal (dogs) Ross et al. (2006)
Talaporﬁn sodium (aspartyl chlorin, Laserphyrin,
Aptocine), Meiji Seika Pharma
664–667 Retained in tumour for 50 h Lung tumours Usuda et al. (2007)
Oesophageal tumours Yano et al. (2017)
Intranasal tumours
(dogs)
Ishigaki et al. (2017)
5-Aminolaevulinic acid (ALA), various
manufacturers
414, 635 Short loading (3 h) ALA: At least 11
different human
tumours
Nokes et al. (2013)
All pro-drugs
(metabolised to
protoporphyrin IX
Short skin photosensitivity (12 h) ALA: Equine sarcoids Golding et al. (2017)
Methyl-ALA (MAL, Metvix), Galderma Epithelial penetration improves in
sequence: ALA > MAL > HAL
MAL: Basal cell
carcinoma
Morton et al. (2008,
2013)
MAL: Equine sarcoids Kemp-Symonds
(2012); Golding et al.
(2017)
Hexyl-ALA (HAL Hexvix), Ipsen HAL: Prostate tumours
(photodynamic
detection)
Furre et al. (2005)
Prostatic carcinoma
(dogs)
L’Eplattenier et al.
(2008)
Verteporﬁn (Visudyne), Novartis 689–693 Binds low density lipoprotein
receptors on abnormal blood vessels
and tumours
Wet macular
degeneration
Scott and Goa (2000)
Oesophagus (dogs) Panjehpour et al.
(2002)
SCC (horses) Giuliano et al. (2014)
SCC, squamous cell carcinoma.
a Applications are for human beings unless stated.
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The development of light sources and delivery devices with the
appropriate dosimetric parameters are key components for the
clinical application of PDT. Accurate delivery of the light to the
tumour tissue can be accomplished by a variety of light sources and
ﬁbre optic delivery devices. Lasers have been one of the main light
sources used in PDT. Modern diode lasers are portable and do not
require specialised electrical supply or water cooling, providing
excellent stability of output power over long periods of time
(Mang, 2004). Diode lasers have been approved for use in human
oesophageal and lung cancer at 630 nm (Photofrin) and at 652 nm
(Foscan) (Yoon et al., 2013).
Alternatives to laser technology are non-coherent light sources
(Reeds et al., 2004) and light emitting diodes (LEDs), the latter
where light is produced by electroluminescence. LEDs are compact,
lightweight and require signiﬁcantly less energy than lasers. LED
systems are capable of output powers up to 150 mW/cm2 over a
3 cm  3 cm area. LEDs have been manufactured with various light
output wavelengths, such as 630, 670 and 690 nm, which can be
used in PDT procedures for ﬂat surface illumination (Mang, 2004,
2009). Light delivery for treatment of large surface areas, such as
treatment of skin diseases, may also be accomplished using broad
spectrum ﬂuorescent lamps (Marcus and Mcintyre, 2002).
However, LEDs have been shown to be more effective than
ﬂuorescent lamps for PDT treatment of SCC (Novak et al., 2016).
One obvious source of light for PDT is the sun; several recent
studies have demonstrated the effectiveness of daylight PDT (See
et al., 2016). Daylight PDT has obvious potential for veterinary skin
cancers, provided the tumour is located where it will be in constant
daylight.
In addition to the light source, delivery devices may be required
to provide penetration of light into the target tissue (Star et al.,
1992). Fibre-optic devices have been developed for PDT light
delivery and dosimetry (Sterenborg et al., 2013). The most widely
used ﬁbre-optic device in PDT is a cylindrical diffusing ﬁbre tip
available in lengths of 1–9 cm depending on the speciﬁc
application. Two light delivery methods have been developed:
intraluminal irradiation using light diffusers for the lung and
oesophagus, and interstitial illumination methods to deliver
adequate light doses to the target tumour volume in head and
neck cancers (Yoon et al., 2013). Fibre optic delivery of PDT has
been used in dogs to treat intramedullary bone tumours (Burch
et al., 2009).
Photodynamic therapy and diagnosis: Clinical uses in human
beings and animals
In contrast to its increasing use in human medicine, the use of
PDT in veterinary medicine has been relatively limited. Although
results from small veterinary clinical studies have been published,
and even though the dog and cat have been used as preclinical
models in several studies (Lucroy et al., 1999, 2003b; Grifﬁn et al.,
2001; Panjehpour et al., 2002; Tanabe et al., 2004), PDT is not well
established as a treatment option for tumour bearing animals to
date. The main indication currently is in treatment of in situ
carcinoma/SCC in cats. Other possible indications are urinary tract
neoplasia and gliomas in dogs, and SCC and sarcoids in horses
(Buchholz and Walt, 2013). The following is a comparative review
of the clinical experience of application of PDT in human and
veterinary medicine. This should provide a basis for future
developments and applications of PDT in veterinary medicine.
Cutaneous tumours
Carcinoma in situ/squamous cell carcinoma
ALA-PDT is mainly used to treat dermatological cancers in
human beings (Morton et al., 2008, 2013; Wan and Lin, 2014). The
results of ALA-PDT in the treatment of human Bowen’s disease
(SCC in situ) have been promising; randomised, controlled trials
comparing ALA-PDT or MAL-PDT to cryotherapy or 5-ﬂuorouracil
(5-FU) cream revealed complete response rates of 82–100% for
PDT, 67–100% for cryotherapy and 79–94% for 5-FU at
12–24 months (Morton et al., 1996; Salim et al., 2003). The
efﬁcacy of topical ALA-PDT in the management of primary
cutaneous invasive SCC is variable, with response rates of
54–100% reported for superﬁcial lesions and recurrence rates of
Table 2
Overview of clinical reports of photodynamic therapy (PDT) for superﬁcial squamous cell carcinoma (SCC) and SCC in situ in cats.
Cases/tumour location PDT agent PDT method Response rate/outcome/side effects References
51 cats
Cutaneous SCC facial
skin
Pyropheophorbid-a-hexyl-ether
(HPPH-23)
IV administration
Argon-pumped dye
laser
Overall 61% response rate at 1 year
100% T1a tumours, 56% T1b and 18% T2b
No toxicity, but some morbidity
Magne et al.
(1997)
4 dogs and 4 cats
Superﬁcial carcinoma
HPPH IV administration
LED (100 J/cm2,
33 min)
8/9 CR
>50% PFS > 68 weeks
No cutaneous photosensitivity
Reeds et al. (2004)
13 lesions/cats
10 nasal planum
2 pinna
1 eyelid
5-Aminolaevulinic acid (ALA),
cream
Topical application
LED 635 nm
12 J/cm2
85% CR rate but with 64% local recurrence (median
21 weeks)
Cats attempt to scratch lesion after treatment
Local analgesia required
Stell et al. (2001)
18 cats
20 cutaneous SCC
Liposomal formulation of Foscan
(m-THPC)
IV administration
625 nm diode laser
100% CR rate
Overall 1-year control rate 75%,
20% recurrence (172 days)
Mild erythema/oedema in 15% of cats
Buchholz et al.
(2007)
55 cats
Superﬁcial SCC nasal
planum
ALA, cream Topical application
LED 635 nm
12 J/cm2
85% CR rate, 11% PR rate, but with 51% recurrence (median
157 days)
Transient, mild, local adverse effects
Bexﬁeld et al.
(2008)
12 cats
Cutaneous SCC
(7 pinna, 2 nasal
planum)
Haematoporphyrin derivative
(Photogem)
IV administration
LEDs (300 J/cm2
30 min)
No response in invasive tumours or pinna
Small non-inﬁltrative lesions of nasal planum (n = 3)
showed CR/PR
One cat developed nasal oedema and died
Ferreira et al.
(2009)
LED, light-emitting diode; CR, complete response; PFS, progression-free survival; PR, partial response.
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0–69%, but with reduced efﬁcacy in more nodular lesions (Wolf
et al., 1993; Morton et al., 2002). Current evidence supports the
potential of topical ALA-PDT for superﬁcial, micro-invasive SCC;
however, topical PDT cannot be recommended for invasive SCC in
view of the metastatic potential of these tumours (Morton et al.,
2008, 2013).
Cutaneous in situ carcinoma/SCC in the cat represents the main
application for PDT in veterinary medicine to date (Fig. 2). A
number of studies have reported response rates from 60% to >80%,
and disease-free intervals >68 weeks, for topical and systemic PDT
in cats using a variety of photosensitisers (Table 2). As is the case in
human patients, the smaller and less invasive tumours respond
best to PDT (Magne et al.,1997). PDT has also been used to treat SCC
in dogs (McCaw et al., 2000), horses (Giuliano et al., 2008), a cow
(Hage et al., 2007), snakes (Roberts et al., 1991) and a great hornbill
(Buceros bicornis) (Suedmeyer et al., 2001).
Basal cell carcinoma
PDT has been employed successfully for treatment of basal cell
carcinoma (BCC) in human patients as a sole agent or in
neoadjuvant setting (Berroeta et al., 2007; Rhodes et al., 2007).
A 92% complete response rate was reported with topical ALA-PDT
in 330 human patients with superﬁcial BCC, but the response rate
dropped to 71% in patients with nodular BCC (Zeitouni et al., 2001).
When topical PDT (with ALA or MAL) was compared to surgery for
BCC, PDTconsistently showed an increased recurrence rate for both
superﬁcial and nodular BCC (Basset-Seguin et al., 2008). This may
be due to insufﬁcient penetration of the photosensitiser to deeply
located tumour cells when the PS is applied topically. To overcome
this problem, the PS may be injected intralesionally. Twenty
human patients with nodular BCC were treated with ALA in 1%
saline solution at estimated dose of 1 mL/cm2 injected into the base
of tumour. PDT resulted in tumour necrosis, followed by complete
re-epithelisation after 4–6 weeks, with good cosmetic results, no
histological evidence of BCC after 3 months and no recurrence
during follow-up of 19.5 months (Rodríguez-Prieto et al., 2012).
Experience of intralesional injection of PS is limited in
veterinary species. One study reported PDT in a cow with ocular
SCC using intratumoural injection of ALA. A complete response was
observed after 3 months and no relapse at 12 months after the
treatment (Hage et al., 2007). A pilot study was conducted using
surgical resection plus PDT for periocular SCC in horses by
inﬁltrating wound beds with HPPH prior to illumination (Giuliano
et al., 2008); this combination yielded disease-free intervals of
25–68 months. The overall recurrence rate was 2/9 (22%) horses;
for those horses where local PDT was the ﬁrst and only treatment
modality used, the recurrence rate was 0%.
Equine sarcoids
Although of ﬁbroblastic rather than of basal cell origin, equine
occult and nodular sarcoids form dermal nodules or plaques and,
as such, bear some physical resemblance to human nodular BCC.
Currently there is no ‘gold standard’ treatment for equine sarcoids;
however, PDT has shown promise in the treatment of these
common and frustrating lesions. Several small studies have
reported encouraging response rates using topical or locally
injected ALA or MAL in equine occult and nodular sarcoids.
Gustafson et al. (2004) achieved a 72% treatment response using
ALA-PDT, with recurrence of 7/18 (39%) lesions after 2 years. Due to
their size, cytoreductive surgery may signiﬁcantly improve the
response for larger lesions. In one study, CO2 laser excision with
adjunctive MAL-PDT achieved 1 year disease-free in 93% of horses
(Kemp-Symonds, 2012). A single application of topical ALA-PDT,
followed by glycolysis inhibition, resulted in successful treatment
of equine sarcoids up to 5 mm thick with a response rate of 25/27
(93%) after 1 month, compared with 1/7 (14%) using ALA-PDT only
(Golding et al., 2017) (Fig. 3).
Prostate cancer
In men, deﬁnitive management of early stage prostate cancer
with either surgery or ionising radiation therapy is associated with
signiﬁcant associated morbidities due to the proximity of nerves,
the urinary bladder and the rectum. In contrast, PDT has the
potential to selectively treat the prostate gland, while sparing the
surrounding normal tissues, because light can be delivered to the
entire gland using interstitial cylindrically diffusing optical ﬁbres.
Prostate cancer is therefore an attractive target for PDT (Agostinis
et al., 2011; Ahmed et al., 2012).
Vascular-targeted PDT using Padeliporﬁn-mediated PDT and a
short drug-to-light interval was shown to carry minimal toxicity in
Fig. 2. Feline nasal squamous cell carcinoma (SCC). (A) An early SCC on the right
nasal planum in a domestic short-haired cat. (B) Application of photodynamic
therapy (PDT) using a high intensity light-emitting diode (LED). (C) Complete
resolution of the lesion at 6 weeks, with minimal scar formation.
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a phase I trial of human prostatic carcinoma patients (n = 24) with
local failure following radiotherapy (Weersink et al., 2005;
Trachtenberg et al., 2007). In a follow-up phase II study, patients
were treated with increasing light doses. At 6 months, all patients
where >60% of the prostate gland was determined to be avascular
by post-PDT magnetic resonance imaging had negative biopsies,
however, 2/28 (7%) patients developed urethrorectal ﬁstulae
(Trachtenberg et al., 2008). Following reﬁnement of the technique,
a recent phase III randomised controlled study of Padeliporﬁn
vascular-targeted PDT (versus active surveillance) has shown this
to be a safe and effective treatment for low-risk localised prostate
cancer (Azzouzi et al., 2017).
The normal canine prostate gland has served as a useful
preclinical model for evaluating responses to PDT in vivo, since its
size and general anatomical structure are similar to those of the
human prostate (Waters and Bostwick, 1997). An experimental
study was conducted assessing Padeliporﬁn PDT on canine
prostate pre-treated with ionising radiation. All dogs had normal
spontaneous urination upon recovery from the procedure, with
no signs of incontinence or signiﬁcant macroscopic haematuria
(Huang et al., 2004).Vascular-targeted photodynamic therapy
with WST11 (TOOKAD Soluble) has been investigated in a canine
model of benign prostatic hyperplasia; in 30 treated dogs,
prostatic urethral width increased as early as 6 weeks after
treatment, while prostatic volume decreased, reaching 25% by
18–26 weeks, this response lasted up to 1 year (Chevalier et al.,
2013); the treatment was well tolerated, with only one dog
experiencing urinary retention. Unfortunately, canine prostatic
carcinoma usually is not detected until clinical signs are
exhibited, at which time the disease is in late stage, often with
metastatic disease, so it is unlikely that PDT would be beneﬁcial in
such cases.
Urinary bladder cancer
Photodiagnosis is used in management of human urinary
bladder cancers (Mowatt et al., 2011) and urinary bladder cancer is
also a potential target for PDT. Human urinary bladder cancers are
often superﬁcial and multifocal, and can be assessed and debulked
endoscopically. Furthermore, the geometry of the urinary bladder
allows for homogeneous light delivery via diffusing ﬁbres. In
general, early response rates (2–3 months) to PDT have been
achieved in 50–80% of human patients and longer-term (1–2 years)
responses have bene achieved in 20–60% of patients. It should be
noted that many of the patients treated in these studies had
recurrent disease that developed after standard therapies, such as
Bacillus Calmette-Guérin (BCG) (Agostinis et al., 2011). Treatment
of superﬁcial urinary bladder cancer with PDT is generally well
tolerated, with dysuria, haematuria, and skin photosensitivity
being the most common acute side effects. Urinary bladder wall
ﬁbrosis/diminished urinary bladder capacity can be a problem in
some human patients (Prout et al., 1987; Uchibayashi et al., 1995).
Studies of locally applied (intravesical) ALA demonstrate that
comparable complete response rates of 52–60% at 2–3 years can be
achieved for human patients with treatment-refractory urinary
bladder carcinoma in situ without the prolonged skin photosensi-
tivity experienced using systemic Photofrin (Berger et al., 2003;
Waidelich et al., 2003). Despite these promising results, PDT for
urinary bladder cancer remains largely investigational with
limited use (Agostinis et al., 2011).
Canine transitional cell carcinoma (TCC) is most commonly
located in the trigone region of the urinary bladder, precluding
complete surgical resection; palliative medical management is
often the only treatment available (Fulkerson and Knapp, 2015).
Photodynamic therapy could represent a promising option for dogs
Fig. 3. Treatment of equine sarcoids. (A) Painting 5-aminolaevulinic acid (ALA) onto a sarcoid. (B) Application of photodynamic therapy (PDT). (C) Appearance of sarcoid at
time of PDT treatment. (D) Appearance of sarcoid one month after PDT.
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with TCC. However, canine TCC is often diagnosed at a late stage
and is more invasive than human urinary bladder cancers, making
comparisons with human studies difﬁcult (Fulkerson and Knapp,
2015). In vitro studies have shown, that ALA-PDT destroys canine
TCC cells (Ridgway and Lucroy, 2003). When studied in vivo, 70% of
dogs vomited after oral administration of ALA, but this did not
appear to have a negative impact on pharmacokinetics, and the
active metabolite (PpIX) was shown to accumulate in the urinary
bladder mucosa, compared to the muscularis and serosa. Five dogs
with TCC of the urinary bladder treated with ALA-PDT and a laser
ﬁbre delivery system showed transient improvement of clinical
signs with tumour progression-free intervals of 4–34 weeks
(Lucroy et al., 2003a,b). The application of PDT for canine TCC
clearly warrants further investigation.
Brain tumours (gliomas)
Experimental and clinical studies have demonstrated that PDT
can complement current standard therapies (surgical resection,
radiation therapy and chemotherapy) in the treatment of brain
tumours in human beings (Muller and Wilson, 1995, 1996). PDT
may be particularly useful as an adjunct to surgery, since it can
non-invasively target tumour cells inﬁltrating the surrounding
brain. Initial trials have provided encouraging results using various
formulations of haematoporphyrin derivatives (HPD, Photofrin),
ALA and m-THPC, with light sources including lamps, dye lasers
and diode lasers (Agostinis et al., 2011). One of the main indications
for ALA in management of human glioma is in ﬂuorescence guided
surgery (FGS). ALA based FGS has been shown to provide longer
survival times than conventional surgery in patients with
suspected malignant gliomas (n = 322; 16.7 versus 11.8 months,
respectively) (Stummer et al., 2006).
In a canine glioma model, 0.75 mg/kg Photofrin-II was
administered intravenously, followed 24 h later by PDT, delivered
using a ﬁbreoptic catheter directly to the tumour via a burr hole in
the skull (Whelan et al., 1993). This destroyed the tumour without
signiﬁcant brain-stem injury.
The new classes of PSs, the better understanding of dosimetry
and further improvements in technology may signiﬁcantly change
the currently achieved clinical outcome for gliomas and other brain
tumours both in human and veterinary patients. Pre-clinical data
indicate that protracted light delivery may increase the therapeutic
index of PDT in the brain, combined with newer technologies, such
as implantable LED-based light delivery systems (Kostron, 2010).
Future perspectives
Photodynamic therapy offers great potential due to its selective
targeting of tumour cells and minimal normal tissue toxicity.
Several innovative strategies have been used to improve PS
penetration into tumour cells, including the use of an electric
current to draw PS deeper into the skin (Lopez et al., 2003),
intratumoural PS injection (Hage et al., 2007; Rodríguez-Prieto
et al., 2012), and pre-treatment with chemical penetration
enhancers (Malik et al., 1995; De Rosa et al., 2000; Golding
et al., 2017), and liposomal formulations and nano-emulsions
(Buchholz et al., 2005, 2007).
The efﬁcacy of PDT may also be improved by overcoming the
antioxidant defences of cancer cells. Antioxidant defences that
remove excess ROS are upregulated in many cancers (Tracootham
et al. 2009), undermining the full potential of PDT. Combination of
glycolysis inhibitors with PDT has been shown to deplete cellular
antioxidants and signiﬁcantly improve PDT cytotoxicity against
human cancer cells in vitro (Golding et al., 2013). This combination
has proved effective in treatment of equine sarcoids (Golding et al.,
2017). Other ways in which the efﬁcacy of PDT may be improved
clinically include metronomic PDT, to deliver both the drug and
light at very low dose rates over an extended period (hours to days)
(Lilge et al., 2000), and the use of nanoparticles for PS delivery
(Bechet et al., 2008). If the potential for use of PDT in veterinary
medicine could be realised, this could make a signiﬁcant
contribution to the overall development of the technique.
Conclusions
PDT is a safe and effective therapy for many cancers and
pre-cancers with external or endoscopic access. Long term clearance
of small, localised lesions can be achieved, with negligible scarringor
damage to adjacent structures. The science of PDT has seen
enormous progress within the past 30 years, including the
development of improved photosensitisers and light sources
(including endoscopic delivery and daylight PDT), improved
understanding of how PDT works, and expansion of the uses of
photosensitisers to allow intraoperative detection of tumour
margins. Although PDT has hitherto been used as a monotherapy,
the future of the technique undoubtedly lies in combining it with
other drugs and approaches as part of a synergistic multimodal
treatment. Despite these scientiﬁc advances, the clinical practice of
PDT is still limited to a small number of individual practitioners or
centres of excellence, partly due to a vicious cycle of high
photosensitiser costs due to limited demand. With pun intended,
veterinary PDT needs to ‘come out of the shadows and into the light’.
This will only happen if PDT becomes a standard part of the training
syllabus and if existing PDT practitioners provide training for the
next generation of veterinarians.The referral system for PDT is also in
need of improvement.
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